Dottikon ES : Shareholders Approve all Proposals of the Board of Directors
July 05, 2019 at 02:28 pm EDT
Share
MEDIA RELEASE
Dottikon, July 5, 2019
DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors
Dottikon, Switzerland, July 5, 2019 - The shareholders approved all proposals of the Board of Directors at the 14th Annual General Meeting of DOTTIKON ES HOLDING AG in Dottikon. The 131 present shareholders represented 1'165'114 voting rights and therefore 95.4% of the total of 1'221'537 registered shares with voting rights.
The Annual Report, the financial statements 2018/19, and the Group financial statements 2018/19 of DOTTIKON ES HOLDING AG were approved by the Annual General Meeting. The Compensation Report 2018/19 was presented to and taken notice of by the Annual General Meeting. Discharge for the business year 2018/19 was granted to the responsible members of the Board of Directors and Senior Management. Further, the proposal of the Board of Directors to carry forward the entire retained earnings to new account and to pay no dividend was accepted. The previous Chairman of the Board of Directors Dr. Markus Blocher was confirmed for another one-year term. Dr. Thomas Früh was reelected for a one-year term as Deputy Chairman and Dr. Alfred Scheidegger as member of the Board. All three Board members were reelected for a term of one year as members of the Compensation Committee. Dr. Markus Blocher was elected as its Chairman and Dr. Thomas Früh as Deputy Chairman. The proposed maximum amounts of prospective remunerations for the Board of Directors and Senior Management, respectively, were approved. KPMG AG, Zug, was reelected as external auditor for another one-year term. Dr. iur. Michael Wicki, attorney-at-law and notary public, was reelected as independent proxy for the 15th Annual General Meeting.
DOTTIKON ES manufactures high-quality performance chemicals, intermediates and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and is positioning itself as strategic development and manufacturing part‑ ner. Its safety culture created over 105 years guides innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing. This shortens conventional chemical synthesis routes, increases yields, selectivities and purities, and reduces waste. The versatile technology and equipment portfolio is used to design, develop and optimize chemical processes, and scale up from kilograms to multi-tons.
DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development as well as clear and transparent communication with customers.
Dottikon ES Holding AG published this content on 05 July 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 July 2019 18:27:10 UTC
Dottikon ES Holding AG is a Switzerland-based holding company that specializes in hazardous chemistry and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industries. Its product range includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, as well as industrial chemicals. Its pharmaceutical products can be found in medications for, among others, heart disease, asthma, high blood pressure and ulcers. Dottikon ES Holding AG's industrial end products include food additives, cosmetics, electro-chemicals, photo-chemicals and agricultural chemicals. The Company also offers distillation plants and thin layer evaporators for the recycling of solvents, as well as high temperature incinerators for the waste treatment of hazardous waste. As of March 31, 2012, the Company had two wholly owned subsidiaries: DOTTIKON EXCLUSIVE SYNTHESIS AG and DOTTIKON ES MANAGEMENT AG. It also held a 33.9%-stake in SYSTAG, System Technik AG.